CSIMarket Company Name, Ticker, Suppliers, else..


Transcode Therapeutics Inc   (NASDAQ: RNAZ)
Other Ticker:  
 


 

Transcode Therapeutics Inc

RNAZ's Financial Statements and Analysis



Transcode Therapeutics Inc narrowed forth quarter of 2024 net loss per share of $-5.65 compare to net loss per share of $-552.61 recorded in the same quarter a year ago a decrease compare to $-5.28 realized in previous quarter.


forth quarter of 2024
Earnings Per Share Revenues
$ -5.65 $  0 Mill
$+546.96     Unch.    



Transcode Therapeutics Inc 's Revenue fell by 0 % in forth quarter of 2024 (Dec 31 2024) year on year, to $0 million and declined by sequentially.


Transcode Therapeutics Inc is

More on RNAZ's Income Statement



Transcode Therapeutics Inc in the forth quarter of 2024 recorded net loss of $-5.947 million, an increase from net loss of $-4.088 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on RNAZ's Growth

Transcode Therapeutics Inc Inventories
RNAZ's Cash flow In the forth quarter of 2024 company's net cash flow was $4 million

More on RNAZ's Cash flow Statement


Transcode Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Transcode Therapeutics Inc earned $ 13.31 cash per share, on a free-cash flow basis .




Company repurchased 0.09 million shares or 19.98 % in Dec 31 2024.


• More on RNAZ's Dividends

 Market Capitalization (Millions) 3
 Shares Outstanding (Millions) 0
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -17
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 10




Transcode Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Transcode Therapeutics Inc had $ 13.31 cash flow per share, on a free-cash flow basis .




Company repurchased 0.09 million shares or 19.98 % in Dec 31 2024.


• More on RNAZ's Balance Sheets

 Market Capitalization (Millions) 3
 Shares Outstanding (Millions) 0
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -17
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 10
   


  News about Transcode Therapeutics Inc Earnings

Transcode Therapeutics Inc Reports Operating Deficit of $-4.059033 Million in Q4 20232.

According to the recent earnings reports, TransCode Therapeutics Inc (NASDAQ...

Transcode Therapeutics Inc's Fiscal Period Sees Decline in Company Results2.

Transcode Therapeutics Inc: An Optimistic Outlook for the Future
As the earning season for the Major Pharmaceutical Preparations industry unfolds, Transcode Therapeutics Inc stands out with its recently disclosed operating shortfall of $-5.327534 million for the period. While the figure may seem discouraging at first glance, it is important to note the contraction from the previous quarter's operating shortfall of $-4.95356 million.
Market participants are now left wondering if Transcode Therapeutics Inc will be able to generate revenue in the near future. The company, however, remains confident as it implements various business strategies to ensure steady growth. Despite the shortfalls experienced d...

Transcode Therapeutics Inc Witnesses Significant Rise in Outlays During Fiscal Second Quarter of 2023



In the Major Pharmaceutical Preparations industry, smaller businesses like RNAZ have recently released their financial results for the second quarter of 2023. RNAZ reported an operating deficit of $-5.130836 million during this period. However, stakeholders remain optimistic, expecting additional business strategies to be implemented in the near future. Meanwhile, despite concerns about the productivity improvement in the industry, RNAZ's management has effectively reduced losses to $-4.342 million. These financial results raise questions about the company's future prospects and the impact these figures may have on its direction.
1. Operating Deficit Impact:
RNAZ's operating deficit of $-5....

Transcode Therapeutics Inc. Faces Rising Working Costs in Financial Time-Frame Closing March 31, 2023

Transcode Therapeutics Inc.: A Closer Look at Their Financial Performance
Transcode Therapeutics Inc. is a biotech company that is focused on the development of RNA-based therapeutics. The company has been in the business since 2016 and has been striving to create a successful business strategy. However, just like any other business entity, they have experienced some rough financial times. In this article, we will take a closer look at Transcode Therapeutics Inc.'s financial performance for the January to March 31, 2023 reporting season.
Stockholder's Expectations vs. Actual Performance
The stockholders of Transcode Therapeutics Inc. did not expect any significant changes during the January to ...


Date modified: 2025-04-16T21:19:30+00:00





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com